| No. of patients who remain on HFNC | HFNC success | No. of patients who remain on HFNC | HFNC failure | P-value | AUROC |
---|---|---|---|---|---|---|
ROX | Â | Â | Â | Â | Â | Â |
 Before initiation of HFNC | 67 | 15.15 (11.90–17.71) | 14 | 14.09 (11.15–16.75) | 0.359 | 0.578 (0.422–0.734) |
 2 h | 67 | 14.41 (10.67–20.00) | 14 | 7.87 (6.52–11.40) |  < 0.001** | 0.822 (0.695–0.949) |
 6 h | 60 | 13.05 (10.92–18.47) | 11 | 8.75 (5.64–18.94) | 0.015* | 0.731 (0.525–0.937) |
 12 h | 53 | 13.06 (10.45–17.01) | 10 | 8.34 (6.35–15.67) | 0.077 | 0.677 (0.450–0.904) |
ROX-HR | Â | Â | Â | Â | Â | Â |
 Before initiation of HFNC | 67 | 17.22 (12.63–21.01) | 14 | 15.63 (12.52–19.63) | 0.284 | 0.591 (0.445–0.737) |
 2 h | 67 | 16.04 (11.67–22.30) | 14 | 8.44 (6.28–11.87) |  < 0.001** | 0.834 (0.719–0.949) |
 6 h | 60 | 14.62 (11.08–20.56) | 11 | 8.75 (5.64–18.94) | 0.006** | 0.763 (0.585–0.941) |
 12 h | 53 | 14.94 (10.98–20.07) | 10 | 9.87 (5.58–19.43) | 0.094 | 0.668 (0.447–0.889) |
ROX-HR-flow | Â | Â | Â | Â | Â | Â |
 Before initiation of HFNC | 67 | 17.80 (14.17–23.17) | 14 | 17.27 (12.52–20.72) | 0.355 | 0.579 (0.430–0.728) |
 2 h | 67 | 18.38 (12.72–24.32) | 14 | 8.77 (6.28–11.95) |  < 0.001** | 0.854 (0.756–0.952) |
 6 h | 60 | 18.25 (11.66–27.01) | 11 | 8.75 (5.64–18.94) | 0.002** | 0.794 (0.636–0.952) |
 12 h | 53 | 17.40 (14.42–23.94) | 10 | 9.87 (5.58–19.43) | 0.020* | 0.734 (0.539–0.929) |